Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States

Background: The Intercept Blood System (IBS) for platelets has been developed to reduce pathogen transmission risks during transfusions. Objective: This study was a comprehensive economic analysis of the cost-effectiveness of using the IBS for single-donor apheresis platelets (AP) and random-donor p...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Christopher E., Botteman, Marc F., Gao, Xin, Weissfeld, Joel L., Postma, Maarten J., Pashos, Chris L., Triulzi, Darrell, Staginnus, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2003
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133650/
https://www.ncbi.nlm.nih.gov/pubmed/14604745
http://dx.doi.org/10.1016/S0149-2918(03)80288-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133650/
https://www.ncbi.nlm.nih.gov/pubmed/14604745
http://dx.doi.org/10.1016/S0149-2918(03)80288-6

Ejemplares similares